Two medicines, side by side
Carvedilol vs valsartan
Carvedilol and valsartan are both labeled for high blood pressure and heart failure. Drugs@FDA records approvals of carvedilol since 1995 and of valsartan since 1996. Pharmacies paid $0.0179 per carvedilol 6.25 mg tablet and $0.0963 per valsartan 40 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, carvedilol is an alpha-adrenergic blocker and valsartan an angiotensin 2 receptor blocker.
Check it at the source: the carvedilol FDA label on DailyMed (effective July 31, 2026); the valsartan FDA label on DailyMed (effective August 5, 2026).
Highlights of the carvedilol record
Carvedilol (Coreg) · label of July 31, 2026
Used for
From the label: indicationsINDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in […]
On the market
- Earliest approval on file
- September 14, 1995
- Generic labelers
- 41 labelers
- Pharmacy cost
- $0.0179 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 22
Highlights of the valsartan record
Valsartan (Diovan) · label of August 5, 2026
FETAL TOXICITY
When pregnancy is detected, discontinue valsartan tablets as soon as possible. ( 5.1 )
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue valsartan tablets as soon as possible. ( 5.1 ).
Used for
From the label: indicationsValsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension, to lower blood pressure in adults and children 6 years and older. […]
On the market
- Earliest approval on file
- December 23, 1996
- Generic labelers
- 34 labelers
- Pharmacy cost
- $0.0963 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 58
Source: FDA drug labels via openFDA (Carvedilol label of July 31, 2026, Valsartan label of August 5, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do carvedilol and valsartan differ on the record?
In FDA's classes, carvedilol is an alpha-adrenergic blocker and valsartan an angiotensin 2 receptor blocker.
How each works, in its label's words: Carvedilol, “COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers …”; Valsartan, “Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).”
Half-life, in each label's words: Carvedilol, “Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 …”; Valsartan, “Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination …”
Only the valsartan label carries a boxed warning.
Generics: carvedilol since 2007; valsartan since 2014 (Drugs@FDA).
| Carvedilol | Valsartan | |
|---|---|---|
| Labeled for | Heart failure, High blood pressure | High blood pressure, Heart failure |
| Pharmacologic class | alpha-Adrenergic Blocker, beta-Adrenergic Blocker | Angiotensin 2 Receptor Blocker |
| How it works (label) | COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. | Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). |
| Half-life (label) | Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. | Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours. |
| Earliest approval on file (Drugs@FDA) | September 14, 1995 | December 23, 1996 |
| First generic approved | September 5, 2007 | June 26, 2014 |
| Generic labelers (NDC) | 41 labelers | 34 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0179 per tablet (Carvedilol 6.25 mg tablet) | $0.0963 per tablet (Valsartan 40 mg tablet) |
| 12-month price change | -4% | -21% |
| Boxed warning | No | Yes |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 22 | 58 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 137,029 | 104,490 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to carvedilol
- every medicine labeled for the same conditions